Printer Friendly

UNIMED HITS ENROLLMENT TARGET FOR MARINOL PHASE III STUDIES IN AIDS PATIENTS

            UNIMED HITS ENROLLMENT TARGET FOR MARINOL
                PHASE III STUDIES IN AIDS PATIENTS
    SOMERVILLE, N.J., Jan. 8 /PRNewswire/ -- UNIMED, Inc. (NASDAQ: UMED) announced today that it has reached its enrollment target for its Phase III studies of Marinol(R) (dronabinol) for appetite stimulation and prevention of weight loss in AIDS patients.
    "With the achievement of our enrollment objectives, we are on schedule for completion of this study and filing of a Supplemental New Drug Application (SNDA) by our target date of July 1992," said Harold J. Tenoso, Ph.D., UNIMED's chairman and chief executive officer.
    Marinol is currently marketed as an antinausea pharmaceutical for the treatment of cancer chemotherapy patients.  Phase III multicenter studies for appetite stimulation and prevention of weight loss in AIDS patients are being conducted in a number of cities around the United States.  Marinol has been granted Orphan Drug designation for this use. Approval of Marinol for this use in AIDS patients and, ultimately, in cancer patients will expand the market in which Marinol competes to over $1 billion worldwide.
    UNIMED, Inc. specializes in the development and marketing of pharmaceuticals, with emphasis on therapy and supportive care of cancer patients and AIDS patients.  The company has brought two pharmaceuticals to market and has a portfolio of drugs in development.
    -0-               1/8/92
    /CONTACT:  Charles P. Harrison, president of UNIMED, 908-526-6894/
    (UMED) CO:  UNIMED, Inc. ST:  New Jersey IN:  MTC SU: PS -- NY050 -- 7625 01/08/92 09:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 8, 1992
Words:244
Previous Article:ACCLAIM REPORTS RECORD FIRST QUARTER REVENUES; PROFITS INCREASE 500 PERCENT
Next Article:GENSIA AND SANDOZ SIGN AGREEMENT FOR DIABETES RESEARCH
Topics:


Related Articles
UNIMED, LECTEC TO PURSUE TRANSDERMAL DEVELOPMENT OF MARINOL
MARINOL RECEIVES APPROVAL AS THE FIRST MEDICATION FOR ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
UNIMED PHARMACEUTICALS STARTS CRYPTOSPORIDIUM CLINICAL TRIAL
UNIMED PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE II CRYPTOSPORIDIUM STUDY; RECEIVES ORPHAN DRUG DESIGNATION
UNIMED PHARMACEUTICALS BEGINS GERIATRIC HYPOGONADISM (ANDROPAUSE) CLINICAL TRIAL
UNIMED PHARMACEUTICALS BEGINS HYPOGONADISM CLINICAL TRIAL; TRIGGERS SECOND BIOCHEM MILESTONE PAYMENT
Unimed Pharmaceuticals Announces NTZ Phase II/III Trial With AIDS Clinical Trials Group
Marinol Found Promising in Treatment of Geriatric Patients with Alzheimer's
Unimed Pharmaceuticals Initiates Phase III Geriatric Hypogonadism Study in Elderly Men
Alzheimer's Disease Experts Join Unimed Advisory Board

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters